Shashi Murthy, Heather Clark
Date of Award
Master of Science
Department or Academic Unit
Bouvé College of Health Sciences, Department of Pharmaceutical Sciences
pharmaceutical sciences, cancer therapy, Doxil, nanoparticles, survivin-siRNA
Pharmacy and Pharmaceutical Sciences
Over the last few decades, cancer chemotherapy has advanced by leaps and bounds and yet cancer has been incurable so far. Cancer, uncontrolled growth of cells, depends on several mechanisms for its proliferation and inhibition of cell death. These processes confer unique properties on the cancer. Even though several unique cytotoxic drugs are available and combination therapies are employed, tumor cells are able to survive in many cases. The tumors develop resistance to most of the therapies rendering the cytotoxic drugs ineffective. Moreover, the chemotherapy tends to cause serious side-effects. As a result, a drug delivery system needs to be developed which will target only the tumors as well as aim at reducing the resistance.
To reduce the resistance of cancer cell lines due to the presence of survivin gene and improve the sensitivity towards doxorubicin, a combinatorial therapy was developed involving the use of liposomes as nanocarriers for the drug and siRNA. Survivin-siRNA was used to induce RNA interference (RNAi) in the cells and reduce the sensitivity. Cationic liposomes were complexed with the siRNA and later coincubated with Doxil (doxorubicin in PEGylated liposomes) to develop the lipoplex-coincubated-liposomes which carried both survivin-siRNA and doxorubicin. These formulations were characterized by size, zeta potential and gel electrophoresis. They were tested for their in vitro cytotoxicity via a cell viability assay against resistant and sensitive cancer cell lines. Moreover, stability studies, cell-uptake studies and Transmission Electron Microscope (TEM studies) were performed. It was found that the combination therapy showed significant improvement in cytotoxicity only in few concentrations and in few cell lines and time periods of treatments. Also, the formulations were not found to be extremely stable over the period of study. Thus, a lack of robustness in the combination therapy and the formulations was observed through these studies.
Bhushan Samir Pattni
Pattni, Bhushan Samir, "Cell toxicity evaluation of lipid-based nanoparticles delivering survivin-siRNA and Doxil in sensitive and resistant human carcinoma" (2011). Pharmaceutical Science Master's Theses. Paper 22. http://hdl.handle.net/2047/d20002573
Click button above to open, or right-click to save.